Eosinophil-Mediated Cholinergic Nerve Remodeling by Durcan, Niamh et al.
Eosinophil-Mediated Cholinergic Nerve Remodeling
Niamh Durcan, Richard W. Costello, W. Graham McLean, Jan Blusztajn, Beata Madziar, Anthony G. Fenech,
Ian P. Hall, Gerard J. Gleich, Lorcan McGarvey, and Marie-Therese Walsh
Department of Medicine, Royal College of Surgeons in Ireland, Beaumont Hospital, Dublin, Ireland; Department of Pharmacology,
University of Liverpool; Division of Therapeutics and Molecular Medicine, University of Nottingham; Department of Medicine,
Queen’s University of Belfast, United Kingdom; Department of Neurology and Neuroscience, Boston University, Boston, Massachusetts;
Department of Dermatology, University of Utah, Salt Lake City, Utah; and Department of Clinical Pharmacology, University of Malta,
Msida, Malta
Eosinophils are observed to localize to cholinergic nerves in a variety
of inflammatory conditions such as asthma, rhinitis, eosinophilic
gastroenteritis, and inflammatory bowel disease, where they are
also responsible for the induction of cell signaling.We hypothesized
that a consequence of eosinophil localization to cholinergic nerves
would involve a neural remodeling process. Eosinophil co-culture
with cholinergic IMR32 cells led to increased expression of the M2
muscarinic receptor, with this induction being mediated via an
adhesion-dependent release of eosinophil proteins, includingmajor
basic protein and nerve growth factor. Studies on the promoter
sequence of the M2 receptor indicated that this induction was initi-
ated at a transcription start site 145 kb upstreamof the gene-coding
region. This promoter site contains binding sites for a variety of
transcription factors including SP1, AP1, and AP2. Eosinophils also
induced the expression of several cholinergic genes involved in the
synthesis, storage, and metabolism of acetylcholine, including the
enzymes choline acetyltransferase, vesicular acetylcholine trans-
ferase, and acetylcholinesterase. The observed eosinophil-induced
changes in enzyme content were associated with a reduction in
intracellular neural acetylcholine but an increase in choline content,
suggesting increased acetylcholine turnover and a reduction in ace-
tylcholinesterase activity, in turn suggesting reduced catabolism of
acetylcholine. Together these data suggest that eosinophil localiza-
tion to cholinergic nerves induces neural remodeling, promoting a
cholinergic phenotype.
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In the airways, parasympathetic nerve stimulation induces ace-
tylcholine release, which leads to mucous secretion and contrac-
tion of bronchial smooth muscle. Since mucous production and
bronchoconstriction are central features of airway diseases such
as asthma and chronic obstructive pulmonary disease (COPD),
the parasympathetic nerves may play a pivotal role in the patho-
genesis of these conditions. There are several key steps in the
synthesis, storage, and release of acetylcholine (ACh). Acetyl-
choline is synthesized from choline and acetyl CoA under the
enzymatic action of choline acetyltransferase (ChAT). ACh is
transported into synaptic vesicles by way of the vesicular acetyl-
choline transporter (VAChT). Once released, ACh stimulates
muscarinic receptors on both target organs and the nerves them-
selves by stimulating M2 muscarinic receptors. M2 muscarinic
receptors function as autoreceptors to limit further ACh release.
ACh is metabolized into choline and acetate by the action of
(Received in original form May 23, 2005 and in final form December 6, 2005)
Supported by the Health Research Board of Ireland and the North-South Program
for collaborative research.
Correspondence and requests for reprints should be addressed to Marie-Therese
Walsh, Department of Medicine, RCSI, Beaumont Hospital, Dublin 9, Ireland.
E-mail: mtwalsh@rcsi.ie
Am J Respir Cell Mol Biol Vol 34. pp 775–786, 2006
Originally Published in Press as DOI: 10.1165/rcmb.2005-0196OC on February 2, 2006
Internet address: www.atsjournals.org
acetylcholinesterase (AChE). Thus, a core group of enzymes
and receptors are responsible for controlling the synthesis, activ-
ity, and turnover of ACh in cholinergic nerves.
Allergic inflammation is associated with the release of neuro-
trophins and other factors that have a direct effect on nerves
(1). One effect of inflammatory mediators is that they can alter
neuronal neurotransmitter content; this effect is termed neural
plasticity. Neural plasticity is widely described in afferent nerves,
but it is not known if cholinergic nerves are similarly subject to
plasticity. Eosinophils are a source of neurotrophins and they
accumulate at cholinergic nerves in human and animal models
of allergic conditions such as asthma, rhinitis, and eosinophilic
gastroenteritis (2–6). Thus, one way in which eosinophils may
cause cholinergic nerve cell remodeling is through the release
of nerve growth factor (NGF). In vitro cell culture studies have
also demonstrated that eosinophil contact with nerves activates
MAP kinases and other signaling pathways in nerves (9). Thus,
eosinophils may influence nerve function via direct contact as
well as by their released factors (6–9). The genes involved in
the synthesis, control of release, and metabolism of ACh are
under the control of a variety of intracellular signaling pathways,
including several protein kinases such as theMAP kinase family.
Therefore, we hypothesized that eosinophil interactions with
nerves may lead to a change in the expression of the genes that
control ACh synthesis and metabolism.
To study this hypothesis we employed an established, in vitro,
co-culture model consisting of eosinophils and the human neuro-
blastoma cell line IMR32. This nerve cell line displays a cholinergic
phenotype when differentiated in culture (6, 7). We studied the
effect of purified eosinophils, eosinophil proteins, and surface
receptors on cholinergic gene expression in this model system. In
addition, we measured the functional activity of the enzymes, the
intracellular acetylcholine content and made preliminary observa-
tions as to which aspect of the M2 muscarinic receptor promoter
sequence was responding to eosinophils. The results indicate that
eosinophils promote a cholinergic phenotype, in particular,
through the release of NGF and eosinophil cationic proteins.
MATERIALS AND METHODS
Materials
DMEM Plus Glutamax, FCS, and penicillin/streptomycin solutions
were purchased from GIBCO/BRL Life Technologies (Paisley, UK).
The IMR32 cell line was obtained from ECACC (Salisbury, UK) and
depleted of fibroblasts using immunomagenetic antifibroblast micro-
beads and LD MACS separation columns (Miltenyi Biotech, Bisley,
UK). TRI Reagent, gentamicin, Trypan Blue, diphenyleneiodinium
(DPI), CDP-Star chemiluminescent substrate solution, Igepal CA-630,
anti-goat IgG alkaline phosphatase (AP) conjugate, phenylmethylsulfo-
nyl fluoride (PMSF), dithithreitol (DTT), and all commonbuffer constit-
uents were obtained from Sigma (Poole, UK). All primers were ob-
tained from MWG-Biotech AG (Ebersberg, Germany). I-Block for
Western blot blocking and Nitro-Block II, chemiluminescent substrate
component for AP, were purchased from Tropix (Bedford, MA).
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Protease inhibitors set, 1st strand cDNA synthesis kit for RT-PCR
(AMV), and LightCycler-FastStart DNA master SYBR Green 1 were
from Roche Molecular Biochemicals (Lewes, East Sussex, UK). Poly-
clonal rabbit anti-human VAChT antibody (H-160, isotype IgG) and
polyclonal rabbit anti-human M2 antibody (H-170, isotype IgG) were
both from Santa Cruz Biotechnology (Santa Cruz, CA, ). Polyclonal
goat anti-human ChAT antibody was obtained fromChemicon Interna-
tional (Temecula, CA). PCR reaction buffer, Taq polymerase, dNTPs,
anti-rabbit IgG AP conjugate, Transfectam reagent, Dual Luciferase
Reporter assay system, andWizard PCRprepsDNApurification system
from Promega (Madison, WI). Image Master VDS-Cl and software
Total Lab v1.00 and Ficoll-Paque PLUS were from Amersham Phar-
macia Biotech (Little Chalfont, UK). CD16 immunomagnetic beads
and VS VarioMacs columns were purchased from Miltenyi Biotech.
Speedy-Diff was obtained from Clin-Tech Ltd (Clacton-on-Sea, UK).
Anti–ICAM-1 and –VCAM-1 antibodies were from Santa Cruz (8).
Eosinophil proteins were prepared as previously described (10).
IMR32 Nerve Cell Culture
The human cholinergic neuroblastoma cell line IMR32 was depleted
of fibroblasts, as described previously (9). The cells were maintained
in culture in proliferation medium (DMEM Plus Glutamax, 5% FCS,
100 U/ml penicillin/streptomycin, 10 g/ml gentamicin) at 37C in an
atmosphere of 5% CO2. On achieving confluence, cells were plated at
a density of 5  105/well in 6-well cell culture dishes and grown in
proliferation medium for 48 h. Proliferation media was then replaced
by differentiation medium (DMEM Plus Glutamax, 2% FCS, 2 mM
sodium butyrate, 100 U/ml penicillin/streptomycin, 10 g/ml gentami-
cin) and cells were used for experimentation after a further 6–7 d of
differentiation in this medium.
Eosinophil Isolation
Eosinophils were prepared from 45 ml of peripheral blood from healthy
human volunteers by a negative immunomagnetic selection technique,
essentially as described previously (6). Only populations of eosinophils
which were  98% pure and  95% viable were used in experimenta-
tion. For experimentation purposes 2 105 eosinophils/well were added
to differentiated IMR32 cells plated as above in 6-well cell culture
plates.
Eosinophil Membrane Preparation
Immediately upon isolation, eosinophils were resuspended in cold, ster-
ile dH2O, incubated on ice for 15 min, then centrifuged at 1,500  g
for 10 min at 4C, as described previously (11). This process was re-
peated twice, and the resulting lysed cell membranes were resuspended
in differentiation medium.
Co-Culture Experiments
Prior studies indicated that 2  105/ml of eosinophils was optimal for
transcription factor activation in IMR32 cells (9–12); therefore, this
number was used for the current studies. IMR32 cells (5  105) were
differentiated for 6–7 d with sodium butyrate as described above and
then incubated with 2  105 eosinophils for varying time periods from
1–48 h at 37C. In some experiments, IMR32 cells were pretreated with
inhibitors of eosinophil adhesion for 30 min or an antibody to nerve
growth factor for 2 h, and co-culture experiments with eosinophils were
performed in the presence or absence of these inhibitors. In other
experiments, IMR32 cells were pretreated with eosinophil membranes,
which contain the eosinophil adhesion molecules but not eosinophil
RNA nor proteins (9). Eosinophil membranes were prepared as de-
scribed above and were added at a concentration equivalent to 1  105
eosinophils.
Nuclear, Cytoplasmic, and Membrane Protein Preparation
Nuclear and cytoplasmic extracts were isolated from IMR32 cells, essen-
tially as described in Ref. 9. For membrane preparations, cells were
rinsed with PBS and detached with 0.5 mM EDTA in PBS at 37C.
The detached cells were pelleted at 6,000 rpm for 5 min and suspended
in 100 l buffer A containing 5 mM Tris (pH 6.8), 2 mM EDTA,
and freshly added protease inhibitors (5 g/ml leupeptin, 0.7 g/ml
pepstatin, 5 g/ml benzamidine, and 1 mM phenylmethylsulfonyl fluo-
ride) at 4C. The cells were forced through a 22-gauge needle five to eight
times, and the lysate was spun in a Beckman Ultracentrifuge (Beckman,
Krefeld, Germany) at 55,000 rpm for 20 min at 4C to collect the mem-
brane pellet. The pellet was resuspended in buffer B containing 20 mM
Tris-HCl (pH 6.8), 150 mM NaCl, 10 mM EDTA, 1 mM EGTA, and
1% Triton X-100 with freshly added protease inhibitors (5 g/ml leupep-
tin, 0.7 g/ml pepstatin, 5 g/ml benzamidine, and 1 mM phenylmethyl-
sulfonyl fluoride) and stored at 80C. Protein concentration was estab-
lished by the Bradford method (13) and extracts were stored at 80C.
Western Blotting
Protein extracts (10 g for M2 analysis or 20 g for ChAT and VAChT
analysis) were heated to 95C in sample buffer (100 mM Tris pH 6.8,
2% [wt/vol] SDS, 0.002% [wt/vol] bromophenol blue, 20% [vol/vol]
glycerol, 10% [vol/vol] -mercaptoethanol) and separated by SDS-
PAGEon 10%polyacrylamide separating gel overlaid with 4% stacking
gel at 500 V for 1 h. The separated proteins were transferred to a
nitrocellulose membrane in transfer buffer (20 mM Tris, 150 mM gly-
cine, 0.01% [wt/vol] SDS, 20% [vol/vol] methanol) at 500 V overnight.
For immunodetection with rabbit anti-human M2 antibody, goat anti-
human ChAT antibody, or rabbit anti-human VAChT antibody, mem-
branes were incubated in blocking buffer (Dulbecco’s PBS [Invitrogen
Ltd, Paisley, UK] containing 0.2% [wt/vol] I-block and 0.1% [vol/vol]
Tween-20) for 1 h at room temperature then incubated for 2 h in
blocking buffer containing the individual respective antibody (1:200 for
each). Following six 5-min washes in washing buffer (PBS [Sigma] pH
7.4, 0.1% [vol/vol] Tween-20) membranes were incubated for 1 h in
blocking buffer containing a dilution of the appropriate anti-goat IgG
(ChAT) (1:10,000) or anti-rabbit IgG (M2, VAChT) (1:7,500) AP conju-
gate.Membranes were thenwashed six times for 5min each and exposed
to CDP Star chemiluminescent substrate solution plus Nitro-Block II
chemiluminescent substrate compound for AP (19:1) for 5 min at room
temperature. Blots were then exposed to X-OMAT light-sensitive film
(Kodak, Stuttgart, Germany) to obtain an image.
mRNA Analysis
Total RNA was isolated from the cells with TRI reagent, according to
the manufacturer’s instructions. For both quantitative LightCycler
PCRs and semiquantitative RT-PCRs, 1 g of total RNA was reverse-
transcribed into cDNA using an oligo (dT)15 primer using the first-
strand cDNA synthesis system. Amplification of cDNA was performed
by quantitative PCR on the LightCycler using fast start Taq DNA
polymerase containing the double-stranded DNA binding dye SYBR
Green 1. The samples were continuously monitored during the PCR,
and fluorescence was acquired every 0.1C. PCR mixtures contained 0.5
M of either -actin–specific primers (forward, 5	 TCC TGT GGCATC
CAC GAA ACT 3	; reverse, 5	 GAA GCA TTT GCG GTG GAC
GAT 3	) M2-specific primers (forward, 5	 GTG GTC AGC AAT GCC
TCA GTT AT 3	; reverse, 5	 TCC CCA TCC TCC ACA GTT CTC
3	) ChAT-specific primers (forward, 5	 TTG TGA GAG CCG TGA
CTG AC 3	; reverse, 5	 CAC AGG ACC ATA GCA GCA GA 3	),
VAChT-specific primers (forward, 5	ATAGTG CCC GAC TAC ATC
GC 3	; reverse, 5	 TCT TCG CTC TCC GTA GGG TA 3	), MnSOD-
specific primers (forward, 5	 AGA TCA TGC AGC TGC ACC ACA
3	; reverse, 5	 GTT CTC CAC CAC CGT TAG GGC 3	), or AChE-
specific primers (forward, 5	 CCT CCT TGG ACG TGT ACG AT 3	;
reverse, 5	 CTG ATC CAG GAG ACC CAC AT 3	). The samples
were denatured at 95C for 10 min followed by 45 cycles of annealing
and extension at 95C for 12 s, 55C for 5 s, and 72C for 8 s (-Actin,
MnSOD, ChAT), 10 s (M2, VAChT), or 6 s (AChE). Characteristic
melting curves were obtained at the end of amplification by cooling
the samples to 65C for 15 s followed by further cooling to 40C for 30
s. Serial 10-fold dilutions were prepared from known quantities of -
actin, M2, ChAT, VAChT, AChE, and MnSOD PCR products, which
were then used as standards to plot against the unknown samples.
Quantification of data was analyzed using the LightCycler analysis
software, and values were normalized to the level of -actin expression
for each sample on the same template cDNA. In semiquantitative
RT-PCR, the integrity of RNA extraction and cDNA synthesis was
verified by PCR by measuring the amounts of -actin cDNA in each
sample using -actin–specific primers (as above). PCR mixtures con-
tained 10 reaction buffer, 2.5 mMMgCl2, 1.25 units ofTaq polymerase,
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and 0.2 mM of each dNTP. Thermocycling conditions for M2 cDNA
were 95C for 5 min, 42 cycles of 95C for 1 min, 55C for 1 min, and
72C for 1 min. Twenty-nine cycles were used to amplify the more
abundant -actin cDNA. A final extension step of 72C for 10 min was
followed by resolution of the 211–bp M2 products and the 314–bp
-actin products on a 1.5% Tris borate-EDTA agarose gel containing
0.5 g/ml ethidium bromide. M2 PCR products were captured and
quantified by densitometry using the Image Master VDS-Cl and soft-
ware Total Lab v1.00.
ACh Measurements
ACh content was determined by high performance liquid chromatogra-
phy with an enzymatic reactor containing acetylcholinesterase and choline
oxidase and an electro-chemical detector using a commercial kit (Bioana-
lytical Systems, Inc., Warwickshire, UK) based on the method of Potter
(14). Protein concentration was determined by the method of Bradford
(13). The cells were pre-incubated for 20 min in a choline-free physiologic
salt solution (pH 7.4) consisting of NaCl 13 mM, KCl 5 mM, CaCl2 1
mM, MgCl2 0.75 mM, glucose10 mM, and HEPES 10 mM. The cells
were then incubated in the same buffer supplemented with neostigmine
(50 M) with or without PMA100 nM for 45 min. The cells were scraped
into 1 ml of methanol, and this mixture transferred to a tube containing
formic acid 100 l 1M, vortex mixed, and centrifuged. The pellet was
collected for protein assay while ACh was extracted by mixing the super-
natant fluid with chloroform and water (1:2:1 vol/vol). The samples were
vortex mixed and centrifuged for 5 min at 3,000 rpm. The aqueous phase
(containing ACh) was collected and dried under a vacuum.
Measurement of Acetylcholinesterase Activity
IMR32 cells (1  106) were homogenized in 200 l of a solution of
50 mM Tris pH 8.0/0.2 mM EDTA (buffer A), centrifuged at 12,000  g
for 10 min, and supernatant was removed. Fifty microliters of 100ug/ml
DTNB (Ellmans Reagent) and 50 l 20 mM acetyl (-methyl) thiocho-
line iodide were added to 50 l cell supernatant. A blank containing
no cells was prepared in tandem. All samples were incubated at 37C
for 5 min. The reaction was followed in a plate reader at 410 nm every
5 min for 20 min. For the initial experiment, supernatants were diluted
1:2, 1:5, 1:10, and 1:20 to determine if the reaction was saturated.
Identification of the Promoter Sequence of the M2
Muscarinic Receptor in IMR32 Nerve Cells
Preparation of promoter deletion constructs and reporter assay analysis
Preparation of RNA, 5	 Rapid Amplification of cDNA ends, cloning,
and sequencing from IMR32 cells were performed as described pre-
viously in human airway smooth muscle cells (15). Regions upstream
of each of the three identifiedmajor transcription start siteswere investi-
gated for promoter activity based on information obtained from the
analysis of the 5	RACE results. Regions upstream of each of the three
identified major transcription start sites were investigated. Each region
was amplified from human genomic DNA using PCR primers with
restriction site consensus sequences for Mlu1 and Xho1built into the
terminal regions of the oligonucleotides. This was necessary to enable
subsequent directional cloning into the pGL3E firefly luciferase re-
porter vector. All PCR reactions were as described in Ref. 15.
Preparation of promoter deletion constructs and transient transfection
of IMR32 cells. Transient transfections were performed using Transfec-
tam reagent. Each clone pGL3E firefly luciferase reporter plasmid was
co-transfected with pRL-SV40, a plasmid that expresses renilla lucifer-
ase under the influence of an SV40 promoter. The latter plasmid was
used as a transfection efficiency control. Transfection solutions, con-
taining 0.75 g cloned pGL3E DNA, 18.75 ng pRL-SV40 DNA (Ratio
50:1), and Transfectam reagent to give a 2:1 ratio, were prepared in
serum-free cell culturemedia. Transfection was performed via the drop-
wise addition of each transfection solution to a well containing differen-
tiated IMR32 cells. Cells were then incubated at 37C 5%CO2 for
48 h. Eight constructs were transfected, as well as an empty pGL3E
plasmid and a nontransfected control. Each vector construct was trans-
fected into six wells, with each individual experiment being repeated
four times. After the 48-h incubation, three wells of each transfected
construct were treated with whole human eosinophils for a further
24 h, while three wells were left untreated. This was also performed
for the empty vector and the nontransfected control.
Dual luciferase reporter assay. Luciferase assays were performed
using the dual luciferase reporter assay system according to the manu-
facturer’s instructions. The 6-well plates were removed from the incuba-
tor, and the growth medium was removed. The wells were rinsed with
PBS and aspirated. Passive lysis buffer was then added to each well,
and the plates were left at room temperature for 15 min. The lysates
were assayed for firefly luciferase activity by the addition of lysate to
luciferase assay reagent II, and luminescence was measured in a Wallac
Victor2 mutilabel counter (PerkinElmer, Boston, MA). Renilla lucifer-
ase activity was subsequently assayed by adding Stop and Glo reagent
and luminometric measurement. Results were normalized for variations
in transfection efficiency by using the ratio of firefly:renilla luciferase
activity as an index of promoter activity. The promoter activity of
each construct was expressed as a fold value over baseline reporter
expression activity (transfection with empty pGL3E vector).
Statistical Analyses
Values are expressed as mean 
 SD. The statistical significance of
differences between treated samples and the appropriate time point
control was evaluated by ANOVA; *P  0.05, **P  0.005.
RESULTS
Eosinophils Do Not Express mRNA for the M2 Muscarinic
Receptor nor Cholinergic Genes
In these control experiments (Figure 1A), RNA was extracted
from 2  106 eosinophils, reverse transcribed, and subjected to
real-time RT-PCR using the relevant primers. Results demon-
strated that eosinophils did not express mRNA for M2 muscarinic
receptors nor the cholinergic genes VAChT, ChAT, and AChase.
However, the -actin gene product was detected in all cases,
demonstrating mRNA integrity. In contrast, all of the above genes
were detected in human IMR32 nerve cell RNA (Figures 1B
and 1C). Figure 1C shows a representative amplification plot,
demonstrating the stability of the -actin message expression.
Eosinophils Induce both M2 mRNA and Protein Production
in Differentiated IMR32 Cells
Real-time RT-PCR analysis revealed a 225% increase in M2
mRNA relative to the untreated control after 24 h of eosinophil
co-incubation with IMR32 cells (*P  0.05) (Figures 2A and
2B). Cellular protein was harvested and separated into cyto-
plasmic and membrane fractions. Western blot analysis using
a polyclonal antibody to the human M2 muscarinic receptor
indicated that M2 protein was expressed only in IMR32 cell
membrane fractions (Figure 2C). Co-incubation of eosinophils
with IMR32 cells for time periods between 1 and 24 h demon-
strated that M2 muscarinic receptor protein levels doubled after
24 h of co-incubation (Figures 2D and 2E).
Adhesion Is Essential but Not Sufficient for Eosinophil-Induced
M2 Protein Expression in Differentiated IMR32 Cells
In prior studies, we have shown that pretreatment of IMR32 cells
with antibodies against both ICAM-1 and VCAM-1 completely
inhibit eosinophil adhesion to nerves (6, 8). When eosinophils
were co-incubated with IMR32 nerve cells in the presence of
these antibodies, no increase in either M2 mRNA or protein
synthesis was observed (Figures 3A and 3B). We then investi-
gated whether contact alone was sufficient to induce changes
in M2 receptor expression similar to those observed following
treatment with whole eosinophils. Eosinophil cell membranes,
which express eosinophil adhesion molecules but not eosinophil
proteins norRNA, were co-incubatedwith differentiated IMR32
cells for 1–24 h with no observed change in M2 expression at
24 h (Figure 3A). These data suggest that adhesion is necessary
but not sufficient to account for the eosinophil-induced changes
in gene expression.
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We have previously shown that eosinophil adhesion to nerves
stimulates the release of eosinophil-derived factors. We then
investigated if the changes in M2 receptor expression were due
to these released factors. Eosinophils synthesize, store, and re-
lease the neurotrophin NGF, which is known to influence cholin-
ergic gene expression (16). We investigated the role of NGF
on eosinophil induced changes in M2 receptor expression by
employing a specificNGF-neutralizing antibody that significantly
Figure 1. Human eosinophils do not express cholinergic
genes. In A, eosinophil mRNA was extracted from 5  106
human eosinophils that had been isolated from a healthy
donor, as described in MATERIALS AND METHODS. The RNA
was then reverse-transcribed and subjected to real-time
RT-PCR for M2, ChAT, VAChT, and -actin. In B, RNA was
extracted from 5  106 IMR32 nerve cells, reverse-
transcribed, and subjected to real-time PCR as described
in MATERIALS ANDMETHODS. The PCR products for ChAT and
-actin (upper panels) and M2, VAChT, and AChE (lower
panels) were identifiable by their characteristic melting
temperatures. The figures are representative of three inde-
pendent experiments.C andD show representative amplifi-
cation plots for the real-time PCR experiments on -actin
(C ) and M2 (D ).
reduced M2 mRNA expression (Figure 3C). By contrast, a nor-
mal goat IgG control had no effect on eosinophil-induced upreg-
ulation of M2 receptor expression (Figure 3D).
Eosinophils contain four unique cationic proteins: eosinophil
major basic protein (MBP), eosinophil-derived neurotoxin (EDN),
eosinophil peroxidase (EPO), and eosinophil cationic protein
(ECP). In the absence of specific neutralizing antibodies to these
proteins, we studied the effect of MBP, EDN, and EPO, as well
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Figure 1. Continued
as all three proteins in combination, on M2 gene expression in
IMR32 cells.We demonstrated that, in combination (M/E/E), these
proteins increased M2 mRNA expression almost 2-fold (Figure
3E). The eosinophil protein concentrations chosen were similar to
those released from eosinophils (1 106/ml) in contact with IMR32
cells (7).
Eosinophils Induce M2 Receptor Expression via Transcription
Start Site 3 in the Human M2 Promoter in IMR32 Cells
The 5	 untranslated region of the M2 muscarinic gene as ex-
pressed in IMR32 cells was identified using a combination of
Rapid Amplification of 5	 cDNA Ends (5	 RACE) and reporter
gene assays. Sequencing of successful 5	RACE clones confirmed
five (A, B, C, E, and F) of the arrangements reported in human
airway smooth muscle (HASM) cells (15). A new arrangement
(G) was also identified (Figure 4A).All the 5	UTRarrangements
identified as a result of 5	RACEexperiments are shown in Figure
4B, together with their lengths. In total, five exons with alterna-
tive splicing patterns separated by introns ranging from 87 bp
to  145 kb were identified, in keeping with recent studies on
both HASM and IMR32 cells. To identify the major regulatory
region(s) of M2 receptor expression in IMR32 cells and to also
specifically identify the regions where eosinophils were exerting
their effects, a series of promoter deletion constructs that spanned
the three transcription start sites (TSS) were designed (Figure
4B). These were used in a series of transient transfection experi-
ments on IMR32 cells that were exposed to eosinophils for 24 h;
luciferase-based reporter assays were subsequently used to detect
activity. The results obtained from IMR32 transfectants treated
with 2  105 eosinophils for a 24-h period (Figure 4C) demon-
strated construct C1 to have higher activity (6.34 
 0.68 [Eos]–
versus 3.12 
 3.30 [Control]–fold over empty vector [n 
 4, P 
0.05]) than C2 (3.62 
 1.65 [Eos]– versus 1.45
1.41 [Control]–
fold over empty vector [n 
 4, P 
 0.05]). Both of these regions
contain sequence upstream of TSS3, suggesting that the major
regulatory region for the muscarinic M2 receptor expression in
response to eosinophils in IMR32 cells lies immediately
upstream of TSS3. With respect to the region upstream of TSS1,
construct C5 showed a significant reduction in activity compared
with controls (0.31
 0.13 [Eos]– versus 0.53
 0.34 [Control]–
fold over empty vector [n
 4,P
 0.05,
 SD]). As low promoter
activity was obtained for all regions upstream of TSS1, se-
quences upstream of TSS1 in IMR32 cells may contain repressor
elements.
Eosinophils Induce ChAT and VAChT mRNA and Protein
Production in Differentiated IMR32 Cells
Eosinophils induced a 5-fold increase in ChAT gene expression
relative to -actin control after 24 h of co-incubation with IMR32
cells (n 
 5, *P  0.05). Western blotting of harvested IMR32
cellular protein fractions (Figure 5A) demonstrated that ChAT
protein was expressed only in the cytoplasmic fraction of IMR32
cells and not in either the membrane or nuclear fractions (Figure
5B). Eosinophil co-incubation with IMR32 cells induced a
2-fold increase in ChAT protein expression by 24 h (Figure 5C).
Real-time RT-PCR demonstrated that eosinophils induced a
132 
 12% increase in VAChT gene expression relative to
-actin control after 1 h of eosinophil co-incubation with IMR32
cells (*P 
 0.05). Western blotting of protein fractions from
IMR32 cells demonstrated that VAChT was only expressed in
the membrane fraction of IMR32 and not in the cytoplasmic
fraction (Figure 5D). Eosinophils co-incubated with IMR32 cells
induced a 2-fold increase in VAChT protein expression after
24 h of co-culture (Figures 5E and 5F).
Eosinophil Adhesion Reduces Acetylcholine Content and
Increases Choline Content in IMR32 Cells
Eosinophil co-incubation with differentiated IMR32 cells over
24–48 h significantly decreased ACh content, with a concomitant
significant increase in choline levels (Figures 6A and 6B).
Eosinophils induce AChE mRNA Production in Differentiated
IMR32 Cells
Real-time RT-PCR demonstrated that eosinophils induced a
modest change of  140% at 1 h and 12 h in AChE mRNA
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Figure 2. Eosinophils induceM2mRNA and protein production in differ-
entiated IMR32 cells. Differentiated IMR32 cells were co-incubated with
2  105 human eosinophils for time periods of 1–24 h. The RNA was
extracted, reverse-transcribed, and subjected to (A) quantitative real-time
RT-PCR on LightCycler, where M2 levels are normalized to -actin (values
are mean 
 SD, n 
 3, *P  0.05, relative to untreated control); or (B )
semiquantitative PCR was performed and M2 and -actin PCR products
were resolved on an agarose gel. In C, Western blot was performed on
membrane and cytoplasmic protein fractions extracted from IMR32 cells
that were exposed to eosinophils for the indicated time points, as de-
scribed in MATERIALS AND METHODS. This experiment demonstrated that
M2 protein was detected only in membrane fractions. In D, Western blot
analysis of IMR32 cell membrane protein fractions of IMR32 cells that
were co-incubated with eosinophils for the indicated times is shown.
Maximal M2 protein expression was observed at 24 h. -Actin was de-
tected after stripping and re-probing of the blot shown inD (upper panel).
In E, the eosinophil-induced change in M2 protein from D is displayed
graphically (values are mean 
 SD, n 
 3, *P  0.05).
relative to -Actin control in IMR32 cells (*P  0.05, Figure
7A). However, functional studies revealed a significant decrease
in the activity of AChE in IMR32 cells after 24 h of eosinophil
co-incubation (Figure 7B).
Eosinophils Do Not Induce MnSOD mRNA Production in
Differentiated IMR32 Cells
In prior studies it has been shown that contact between eosino-
phils and nerves led to the generation of oxygen free radicals
in IMR32 nerve cells (8, 12). Furthermore, it has also been
demonstrated that these free radicals were important intermedi-
ate signals involved in NF-B activation in the nerve cells con-
trolling nerve growth (9–11). Thus, we investigated whether the
antioxidant gene, MnSOD, was also effected by eosinophil co-
culture with nerves. RT-PCR demonstrated that in IMR32 cells
eosinophils did not induce an increase in MnSOD mRNA at
any of the time points studied (Figure 8).
DISCUSSION
The effects of eosinophil co-culture on cholinergic gene and
protein expression in the cholinergic nerve cell line IMR32 were
addressed in this study. Of particular interest was the muscarinic
M2 receptor, the cholinergic enzymes ChAT (instrumental in
acetylcholine synthesis) and VaChT (responsible for ACh pack-
aging), and the ACh hydrolysing enzyme AChE. The results
obtained indicate that eosinophils alter the cholinergic pheno-
type of IMR32 cells. We observed that eosinophils increase M2,
ChAT, and VAChT mRNA and protein production after 24 h
of co-culture. Furthermore, this led to increased ACh turnover
and a significant decrease in AChE enzymatic activity. There
was no alteration in gene expression of the antioxidant enzyme
MnSOD at any of the time points studied, indicating that the
observed changes in cholinergic genes were specific and not part
of a generalized change in gene expression. Thus, eosinophils
induce a muscarinic receptor that controls the release of ACh
from nerves, induce the enzymes involved in the synthesis and
storage of ACh, and cause a loss of function of the enzyme,
which is responsible for the hydrolysis of acetylcholine. Together
these data suggest that eosinophils promote and enhance the
release of ACh from cholinergic nerve cell terminals.
It is known that the signaling molecules PI3 kinase, PKA, and
the MAP kinases are involved in regulating the expression of
ChAT, VAChT, and the M2 muscarinic receptor via a series
of signaling pathways (17–19). In vitro, we have shown that
eosinophils adhere to nerve cells via specific adhesion molecules
and subsequently release factors that induce signaling pathways
in nerve cells (9). Since eosinophils are known to promote airway
remodeling in asthma, and since the expression of cholinergic
genes is controlled by eosinophil-activated signaling pathways,
we investigated whether eosinophils were responsible for the
activation of these genes in cholinergic nerve cells.
In this study, M2 receptor protein levels increased by at least
2.5-fold after 24 h of eosinophil co-culture. Experiments were
undertaken to demonstrate the mechanisms underlying these
changes. First, it was shown that eosinophils need to be adherent
to nerves via the adhesion molecules ICAM-1 and VCAM-1 to
induce M2 receptor expression, as no alteration in gene expres-
sion was observed in the presence of adhesion inhibitors. How-
ever, adhesion alone was insufficient to induce M2 expression,
as a preparation of isolated eosinophil membranes did not induce
these changes. Therefore, eosinophil adhesion led to the release
of eosinophil factors that were responsible for changes in cholin-
ergic phenotype, as we have previously described (8, 12). Func-
tional studies revealed that this increased expression of M2 was
due to released NGF and eosinophil cationic proteins, as M2
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Figure 3. Eosinophil-induced M2 gene and pro-
tein expression in differentiated IMR32 cells is de-
pendent on eosinophil adhesion and released fac-
tors such as NGF and eosinophil proteins. In A,
differentiated IMR32 cells were either pretreated
with antibodies against VCAM-1 and ICAM-1 and
then co-incubated with 2  105 isolated eosino-
phils for 24 h, or were co-incubated with purified
membranes isolated from 2  105 human eosino-
phils for 24 h. RNA was extracted, reverse-
transcribed, and subjected to quantitative real-
time RT-PCR (n 
 3, *P  0.05, relative to
untreated control). Neither eosinophil mem-
branes nor whole eosinophils in the presence of
blocking antibodies inducedM2 mRNA expression
in differentiated IMR32 cells. M2 levels were nor-
malized against the housekeeping gene -actin.
B showsWestern blot analysis depictingM2 protein
levels in IMR32 cell membrane fractions that were
pretreated with the blocking antibodies described
above and then co-incubated with 2 105 human
eosinophils for up to 48 h. Figure is representa-
tive of three independent experiments. (C and D)
Differentiated IMR32 cells were either left untreated
or were treated with (C ) an NGF-neutralizing anti-
body (0.08 ng/ml) or (D ) an equivalent amount of
normal goat IgG, and subsequently co-incubated
with 2  105 human eosinophils for 24 h. Cellular
RNA was extracted, reverse-transcribed, and sub-
jected to quantitative real-time RT-PCR (n 
 4,
*P 
 0.05, when compared with untreated con-
trol). In E, the effect of eosinophil proteins on M2
receptor expression in IMR32 cells is shown. The
eosinophil granule proteins MBP, EPO, and EDN
were incubated with IMR32 cells both separately
and in combination (M/E/E) for 24 h. Cellular RNA
was extracted, reverse-transcribed, and subjected
to quantitative real-time RT-PCR (n
 3, *P 0.05,
when compared with untreated control).
gene expression was induced at 24 h by MBP (170%) and EPO
(300%), suggesting these proteins play a part in the change
induced by whole eosinophils (245%). Interestingly, treatment
with EDN significantly decreased M2 expression (50%). When
cells were treated with a combination of all three proteins, M2
expression was seen to increase significantly (190%), but not
achieving levels as high as that of whole eosinophils.
From this study, it appears that M2 expression is negatively
regulated by factors as yet unidentified. It is possible that EDN
could play an important role in this regulation. It is known to
possess potent RNase activity which may explain in part the
absence of the M2 gene at the later time points. That is, it may
specifically target a factor necessary for M2 transcription or it
may directly affect M2 mRNA.
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Figure 4. Eosinophil induced increase in promoter
activity is due to activation of transcription factors
in the TSS 3 region. (A ) Identified arrangements,
obtained by DNA sequencing analysis, in the hu-
man muscarinic M2 receptor 5	UTR in IMR32 cells
(CDS, coding sequences; boxed region, exonic se-
quence; lined region, intronic sequence). B shows
the eight regions of theM2 receptor 5	 UTR, which
were amplified for pGL3E cloning. These different
constructs cover the three main transcription start
sites shown. Luciferase reporter activity for IMR32
transfectants (C ) were culturedwith () orwithout
() eosinophils for 24 h. Data are expressed as
fold values over empty vector baseline control
(n 
 4, 
 SD, *P  0.05, when compared with
nontransfected control).
To identify the promoter region(s) of IMR32 cells that exerts
the most significant regulatory control over M2 transcription
in response to eosinophil co-culture, we initially identified the
transcription starts sites in IMR32 cells and subsequently per-
formed reporter gene studies. Analysis of the sequence data
arising from 5	RACE experiments identified the presence of six
different mRNA transcripts. The region also contains five exons
of which Exon 2 and Exon 5 are alternatively spliced. The experi-
ment confirmed the earlier published results (15, 20), and also
identified one new transcript arrangement (G) (Figure 4D). We
identified three regions of transcription initiation in the human
muscarinicM2 receptor gene 5	UTR,with each region containing
a cluster of specific transcription start sites (TSSs) in close prox-
imity to each other. The most 5	 TSS lies more than 146 kb
upstream from the ATG start codon of the gene.
The M2 coding sequence is preceded by a 46-bp exon that is
expressed in all mRNA transcripts we obtained. Upstream of this,
we have identified four additional exons, of which exons 5 and 2
are alternatively spliced. Our data suggest that the TSS1 region
appears to be the most commonly used transcription start site (23
out of 46 clones), whereas TSS2 is the rarest (3 out of 46 clones).
Reporter gene expression analysis performed on IMR32 cells,
transiently transfectedwith pGL3Enhancer constructs, provided
data that strongly suggest that the major regulatory region lies
immediately upstream of TSS3. In addition, it would appear that
repressor elements could operate upstream of TSS1, which is
supported by the fact that construct 4 induces decreased expres-
sion of M2 compared with construct 3. Also, all constructs con-
taining regions upstream of TSS2 displayed low activity levels.
The human muscarinic M2 receptor promoter, similar to all
muscarinic receptor promoters identified, is TATA-less. Sp1,
AP1, AP2, and GATA transcription factors have previously
been cited as relevant for TATA-less promoters (21–26). In view
of this it is interesting to note that the highest incidence of
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Figure 5. Eosinophils induce ChAT and VAChT production in
differentiated IMR32 cells. Differentiated IMR32 cells were co-
incubated with 2  105 human eosinophils for the indicated
time points. In A, RNA was extracted, reverse-transcribed, and
subjected to quantitative real-time RT-PCR and ChAT levels
normalized against -actin (n 
 3, **P  0.005, when com-
pared with untreated control). In B, Western blot analysis of
IMR32 cell cytoplasmic, membrane, and nuclear fractions
demonstrated that ChAT protein was expressed solely in cyto-
plasmic fractions. InC, co-incubation of IMR32 cellswith eosin-
ophils led to an increase in ChAT protein expression in cyto-
plasmic fractions, which wasmaximal at 24 h. InD, a graphical
representation of Western blot analyses demonstrated that
ChAT protein expression was significantly increased relative
to control after 24 h of co-culture (Figures are representative
of three independent experiments). In E, Western blot analysis
membrane and cytoplasmic fractions from IMR32 cells demon-
strated that VAChT protein was present only in membrane
fractions and that eosinophil-induced increases in VAChT pro-
tein expression were maximal at 24 h. In F, co-incubation of
IMR32 cells with eosinophils for 24 h led to a significant in-
crease in VAChT protein expression relative to -actin. Figures
are representative of three independent experiments.
Sp1, GATA, and AP sites lies within the region of maximum
transcriptional regulatory activity, immediately upstream of
TSS3. We have previously shown that eosinophil MBP can in-
duce AP transcription factor activation in IMR32 cells (9), but
further studies will be required to establish which transcription
factors are involved in eosinophil-induced activation of the M2
receptor.
ACh is synthesized from choline and acetyl CoA under the
enzymatic action of ChAT and is transported into the synaptic
vesicle by the action of VAChT, where it is stored until required.
Twenty-four hours of eosinophil co-culture with IMR32 nerve
cells led to an increase in ChAT and VAChT protein levels. At
the same time, choline levels are seen to increase by at least
3-fold. These facts suggest that the increased levels of intracellu-
lar choline are due to an increase in choline uptake in order for
de novo ACh synthesis to occur. There is also a corresponding
increase in ChAT enzyme levels, leading to increased amounts
of ACh. However, VAChT protein levels are also increased,
suggesting increased packaging of the newly synthesized ACh
into vesicles. These facts suggest a rapid turnover of ACh such
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choline content in differen-
tiated IMR32 cells. In A,
ACh levels in differentiated
IMR32 cells that have been
treated with eosinophils for
the indicated times were
seen to decrease after 24 h
of co-incubation. In B, cho-
line levels in differentiated
IMR32 cells that have
been treated with eosino-
phils for the indicated
times increased after 24 h
of co-incubation. ACh and choline were quantified by HPLC, as de-
scribed in MATERIALS AND METHODS (n 
 4, *P 
 0.05, **P  0.01, when
compared with untreated control).
that intracellular ACh levels fall quickly and extracellular levels
are high. Indeed, overexpression of VAChT in immature xeno-
pus neurons increased the amount of neurotransmitters released
by synaptic vesicles (27). Similar results were obtained for the
related molecule VMAT2 (a monoamine transporter), which
demonstrated that increasing its expression in mature synaptic
vesicles actually increased transmitter release (28). This is sup-
ported by our prior experiments, which demonstrated an in-
crease in the spontaneous release of ACh from nerves after
exposure to eosinophils (6, 7). Specifically, we demonstrated
that when eosinophils are added to IMR32 cells, they enhance
acetylcholine release by 36% (7).We have also previously shown
that eosinophils degranulate in response to adhesion to IMR32
cells (6, 8). MBP is a major eosinophil degranulation product
and is a selective allosteric antagonist at theM2 receptor (29–31),
Thus release of MBP from eosinophils renders the M2 receptor
Figure 7. Eosinophils in-
duce a minor increase in
AChEmRNA production in
IMR32 cells with an ac-
companying fall in its ac-
tivity. In A, differentiated
IMR32 cells were co-
incubatedwith 2 105 hu-
man eosinophils for the





LightCycler as described in
MATERIALS AND METHODS.
AChE levels were normal-
ized against -actin (n
 8,
*P  0.05, when com-
pared with untreated
control). In B, AChE activ-
ity was quantified as de-
scribed in MATERIALS AND
METHODS, with an ob-
served decrease in AChE
activity after 24 h of eosin-
ophil co-incubation.
Figure 8. Eosinophils do not
induce MnSODmRNA produc-
tion in differentiated IMR32
cells. Differentiated IMR32 cells
were co-incubated with 2 
105 human eosinophils for time
periods of 1–24 h. RNA was
extracted, reverse-transcribed,
and subjected to quantitative
real-timeRT-PCRonLightCycler
as described in MATERIALS AND
METHODS. MnSOD levels were normalized against -actin. Figure is rep-
resentative of three independent experiments.
dysfunctional, resulting in the increased ACh release we refer
to above. The effect of this protein is an important cause of M2
receptor dysfunction and enhanced vagally mediated broncho-
constriction in asthma. It may be that the observed increase in
M2 expression in response to eosinophils and to MBP and EPO
is an attempt to overcome this antagonistic effect.
Levels of ACh esterase were seen to increase modestly be-
tween 1 and 12 h, but this was not maintained beyond 12 h. As
an alternative to Western blotting for AChE protein, enzyme
activity was measured, as results obtained would be of greater
functional significance. After 24 h of eosinophil co-culture with
nerve cells, there was a fall in AChE activity. This may be of
some significance, as loss of AChE activity would be expected
to lead to increased neurotransmission via ACh and augment
the effect of the other changes seen in this system (i.e., increased
cholinergic activity). There have been prior studies in a number
of animal models of loss of function of acetylcholinesterase (27,
32–48). The observation of decreased acetylcholinesterase activ-
ity in the context of a modest increase in acetylcholinesterase
protein expression may seem contradictory. Acetylcholinester-
ase exists in multiple molecular forms, which are differentially
inactivated in different cell growth conditions (49). Therefore,
depending on what molecular form is predominantly present, it
could be inactivated in our cell system. However, another possi-
ble explanation is that in this manuscript we measured the ex-
pression of cell-associated acetylcholinesterase, not soluble cell-
free acetylcholinesterase. In other cells, most acetylcholinester-
ase enzymatic activity ( 80%) is detected in the cell growth
medium as soluble acetylcholinesterase, both in humans and in
other species (50, 51). Therefore, in this context it is not unex-
pected that increased acetylcholinesterase cell-associated pro-
tein expression does not correspond to increased activity.
Several control experiments were performed to verify the
specificity of these results. First, we investigated whether the
eosinophils caused nerve cell death. Previous studies and our
own preliminary studies indicated that co-culture of eosinophils
with IMR32 cells did not lead to significant apoptosis of either
the nerves or the eosinophils when they were maintained in co-
culture for as long as 96 h (12). Indeed, we have shown that
eosinophils and their degranulation proteins protect IMR32 cells
from apoptosis (52, 53). Second, to avoid potential contamina-
tion by gene products contained within eosinophils, mRNA ex-
tracted from eosinophils was subjected to RT-PCR. In all cases
there was no detection of cholinergic genes or the M2 muscarinic
receptor. Therefore, the increase in M2 receptor, ChAT, AChE,
and VAChT mRNA expression observed were due to changes
within IMR32 cells alone. Similar experiments were also per-
formed on eosinophil total protein to verify the absence of the
corresponding proteins. Western blotting analysis with specific
antibodies also failed to detect any of the proteins of interest in
eosinophil total protein. The choice of eosinophil concentration
Durcan, Costello, McLean, et al.: Eosinophil-Mediated Nerve Remodeling 785
used for these co-culture experiments was based on prior studies
performed in the laboratory. Dose–response studies indicated
that 2  105/ml of eosinophils was optimal for transcription
factor activation in 5  105 IMR32 cells; therefore this number
was used for gene expression studies. Also, to confirm that the
changes in enzymes were of physiologic significance, we also
measured the levels of ACh and enzymatic activity of the acetyl-
cholinesterase activity. Finally, to assess the specificity of the
changes induced by eosinophils, we measured changes in the
antioxidant gene MnSOD. This was measured because adher-
ence of eosinophils to IMR32 cells in culture induces free radical
production in the IMR32 cells, as assessed by oxidation of dihy-
drorhodamine 123. However, no change in MnSOD mRNA
levels was observed following eosinophil co-culture.
Since M2 levels are increased, it would be expected that there
would be a decrease in vagally mediated bronchoconstriction,
as M2 acts as an autoreceptor limiting the excessive release of
ACh. However this does not seem to be the case in pathologic
states such as asthma. Prior functional studies have shown that
M2 receptors are inhibited by eosinophil MBP (29–31). Thus,
combining this data with the current observations, we suggest
that the increased ACh released from eosinophil-stimulated
nerves would be unable to bind M2 receptors but still able to
bind M3 receptors, which are not inhibited by MBP, resulting
in increased vagally mediated hyperreactivity (30).
The results of this study show that eosinophils have a pro-
found effect on cholinergic gene expression in IMR32 cells,
which tend to promote a cholinergic phenotype. These effects
are exerted via eosinophil adhesion and factors released from
eosinophil granules after adhesion, including the cationic pro-
teins MBP and EPO and also NGF. Release of NGF and other
neurotrophins may contribute significantly to nerve remodeling
in asthma and other allergic diseases. Our results show that
NGF released from eosinophils contributes significantly to the
observed upregulation ofM2 receptor expression. Neurotrophins
including NGF are survival factors for eosinophils (1); therefore,
release of NGF would tend to perpetuate the effects of eosino-
phils on nerve cells, as well as exerting direct effects on the nerve
cells. NGF has previously been implicated in the pathogenesis of
allergic illness (reviewed Refs. 54 and 55). Its circulating levels
are increased in allergy and it induces hyperresponsiveness of
isolated human bronchus (56). Effects on bronchial hyperrespon-
siveness maybe due to NGF-induced increases in innervation.
However, our results imply that in allergy, eosinophil-derived
NGF may also directly affect nerve cholinergic phenotype, con-
tributing in this way to ACh release, nerve hyperreactivity, and
remodeling and thus to bronchial hyperresponsiveness.
To summarize, this work has demonstrated that increased
expression of the M2 muscarinic receptor in IMR32 cells results
first from eosinophil adhesion to nerve cells and second from
the products subsequently released by eosinophils; including the
cationic proteins and NGF. The study characterized the 5	 UTR
of the human muscarinic M2 receptor gene and has defined
sites of transcriptional regulation by eosinophils. In addition,
the studies have shown an eosinophil-induced increase in the
turnover and release of ACh and a reduction in acetlycholinest-
erase activity. Together these data suggest that eosinophils pro-
mote cholinergic nerve cell remodeling, a feature ofmany clinical
manifestations (among them asthma).
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